

1/17





FIG. 1



3/17




FIG. 2g

4/17




FIG. 2H1




FIG. 2H2




FIG. 2H3




FIG. 2H4

5/17




FIG. 2i

6/17




FIG. 3

7/17




FIG. 4

8/17




FIG. 5



9/17




FIG. 6

10/17




FIG. 7

11/17

a. 1 2 3 4 5



-5kb-  
-2.4kb-

b. 1 2 3 4 5



c. 1 2 3



-5kb-  
-2.4kb-

d. 1 2 3



FIG. 8

12/17




FIG. 9

13/17




FIG. 10C




FIG. 10B




FIG. 10A




FIG. 11A

vector	cell line	neo protein	titer
VLPBN	GPE86	3.4ng/mg	1.65 x EE4
VLPPBN	GPE86	1.57ng/mg	5.6 x EE4
VLCN	GPE86	3.74ng/mg	2 x EE5
VLDN	GPE86	3.87ng/mg	7.5 x EE4
VLPBN	PA317	1.25ng/mg	ND
VLPPBN	PA317	1.92ng/mg	ND
VLCN	PA317	1.59ng/mg	ND
VLDN	PA317	1.77ng/mg	ND

FIG. 11B

14/17




FIG. 12A




FIG. 12B

15/17




FIG. 12C




FIG. 12D

16/17




FIG. 13A




FIG. 13B




FIG. 13C



17/17

VL30-MVM HYBRID FOR TUMOR EXPRESSION




FIG. 14